恒指26,300失而复得 汇控等银行股捱沽 惟小米及药明生物升逾4%再破顶
虽然美国国会两党就9,000亿美元抗疫新刺激方案达成协议，方案包括延长额外失业救济及向大多数美国民众「派钱」等。不过，美股期货先弹後回，蓝筹股指期货倒跌，其中道指期货由最高30,333，掉头低见30,078，现造30,110，倒跌3点；但纳指期货回升0.2%。
亚洲多国疫情反弹，亚太区股市今早普遍反覆受压，但跌幅均少1%，其中日经高见26,905再创逾29年半高遇阻曾低见26,533，现造26,601，续吐0.6%。不过，沪指及深成逆市反覆回升近0.5%及1%，分别报3,410及13,985。
美国商务部上周五(18日)以保护美国国家安全和外交利益为由，将包括中芯(00981.HK)等60多间中资企业列入实体清单；加上本港疫情仍然严峻，恒指延续上周五回吐势，今早低开75点报26,422，跌幅曾扩至223点低见26,274获承接，现造26,424，跌73或不足0.3%，成交额额396亿元。
蓝筹股普遍受压，银行股无一幸免，尤其是汇控(00005.HK)低见39.65元，现造39.75元，续跌3.4%；中银(02388.HK)三连跌，报23.25元，续跌1.7%。相反，三大保险股反覆向好，其中友邦(01299.HK)扭两连跌，股价重越10天线，报90.3元，回升0.9%。
地产股以恒隆地产(00101.HK)、新世界(00017.HK)、润地(01109.HK)及中海外(00688.HK)跌幅最大，分别报19.2元、36.7元、30.85元及17.52元，跌1.7%-2.1%。此外，上周五急涨中移动(00941.HK)及联通(00762.HK)回吐2.7%及2.9%，分别报44.35元及4.43元，前者重失10天及20天线，後者重失20天线。
腾讯(00700.HK)及阿里巴巴(09988.HK)续跌逾1%，分别低见571.5元及251.6元。不过，小米(01810.HK)继上周五整固後，今早反覆再破顶，报30元即市高位，回升4.2%。安踏(02020.HK)扭两连跌，股价重越20天及10天线(108.7元及109元)，最高见109.3元，现造109元，回升3.7%。此外，药明生物(02269.HK)升破上周尾所创纪录高位88元，报91元，续升近4.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
